(64)Cu-diacetyl-bis(N(4)-methylthiosemicarbazonate), (64)Cu-ATSM, continues to be investigated clinically as a PET agent both for delineation of tumor hypoxia and as an effective indicator of patient prognosis, but there are still aspects of the mechanism of action that are not fully understood.The retention of radioactivity in tumors after administration of (64)Cu-ATSM in vivo is substantially higher for tumors with a significant hypoxic fraction. This hypoxia-dependent retention is believed...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher copy:
- Society of Nuclear Medicine Publisher's website
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine Journal website
- Publication date:
- Source identifiers:
- Local pid:
- Copyright holder:
- Society of Nuclear Medicine and Molecular Imaging, Inc.
- Copyright date:
A comparison of the behavior of (64)Cu-acetate and (64)Cu-ATSM in vitro and in vivo.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record